Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics develops antibody drugs for inflammatory bowel disease and rheumatic conditions. It last closed at $93.81 on Nov 17, down 5.60% on the day. The average 12-month price target from 6 analysts is $122.17 (+30.2% from the last close), with a high of $135.00 and a low of $110.00. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (6 buy, 0 hold, 0 sell).
Key Stats
Fiscal 2025Not reported for this period.
From SYRE's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Nov 3).
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 6 analysts who set a price target on SYRE in the past 90 days. The average target is $122.17, with a high of $135.00 and a low of $110.00, compared with the last close of $93.81.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 4 | Guggenheim | Target raised | Buy | $130 → $135 |
| Nov 4 | Wedbush | Target lowered | Buy | $123 → $120 |
| Oct 12 | UBS | Initiated | Buy | $120 |
| Oct 1 | JP Morgan | Initiated | Buy | $110 |
| Oct 1 | BTIG | Reiterated | Buy | $121 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is 18% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 46). The nearest support is the swing low (Nov 4) at $92.77, and the nearest resistance the 100 day average at $94.94.
| RSI (14) | 46.23 | Middle of its range | Neutral |
| MACD | 2.89 | Below its signal line | Bearish |
| Stochastic | 35.5 | Middle of its range | Neutral |
| ADX (14) | 16.7 | No clear trend | |
| Williams %R | -94.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -52.0 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −5.5% | Change over 10 sessions | Bearish |
| ATR (14) | $5.33 | Typical daily range, 5.7% of price |
| RSI (14) | 55.13 | Middle of its range | Neutral |
| MACD | 6.54 | Below its signal line | Bearish |
| Stochastic | 70.5 | Middle of its range | Neutral |
| ADX (14) | 35.6 | Trending up | |
| Williams %R | -49.8 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 29.4 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +3.5% | Change over 10 sessions | Bullish |
| ATR (14) | $10.96 | Typical daily range, 11.7% of price |
What happened before
See how SYRE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How SYRE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.
Whale Options Flow
90DNo whale options trades in SYRE in the last 90 days.
SYRE Institutional Ownership
Full report →- ▲188 buying vs 121 selling
- ▲Held by funds +5.5 pts
- ▲Funds holding +20
- ▲Superinvestors: 2 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 286 | 266 | +7.5% |
| In funds' top 10 | 11 | 12 | −8.3% |
| Held by funds | 106.5% | 100.9% | +5.5 pts |
| New / increased | 66 / 122 | 89 / 103 | −2.1% |
| Reduced / sold out | 76 / 45 | 55 / 22 | +57.1% |
| Put/call ratio | – | 6.95 | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SYRE is in one of them and how their past SYRE trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered SYRE in an article yet. Here's the latest on the wider market.
About Spyre Therapeutics
Spyre Therapeutics is a biotechnology company based in Waltham, Massachusetts, that develops antibody medicines. Its drug candidates are designed to act on the immune system and to last longer between doses, with the aim of treating inflammatory bowel disease, which includes ulcerative colitis and Crohn's disease. The company is also studying its anti-TL1A antibody for rheumatic conditions such as rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. Its target patients are people living with these chronic immune conditions, and its products are still in development rather than on the market.
- Headquarters
- Waltham, MA
- Founded
- 2013
- Website
- aegleabio.com ↗


